-
P126849-500mgPalbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
-
P126849-50mgPalbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
-
P424820-1mlPalbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
-
-
-
-
-
-
P129976-100mgPancuronium dibromide is a competitive acetylcholine antagonist with an IC50 of 5.5 nM.A nicotine neuromuscular antagonist.
-
P129976-1gPancuronium dibromide is a competitive acetylcholine antagonist with an IC50 of 5.5 nM.A nicotine neuromuscular antagonist.
-
P129976-250mgPancuronium dibromide is a competitive acetylcholine antagonist with an IC50 of 5.5 nM.A nicotine neuromuscular antagonist.
-
P591008-100mgPancuronium dibromide.